US military has designs on faster drugs

Kiernan, Vincent
June 1994
New Scientist;6/25/94, Vol. 142 Issue 1931, p22
Focuses on an American nuclear weapons laboratory's use of supercomputers to model the behavior of potential drugs against cancer and cardiovascular disease. Use of simulation software; Improvement in selection of promising drugs; Cost and time advantages.


Related Articles

  • Trials `a must' for disputed cholesterol drugs. Vines, G. // New Scientist;2/22/92, Vol. 133 Issue 1809, p11 

    Reports on the dispute in Great Britain over cholesterol-lowering drugs. The need for large trials of a new generation of these drugs, known as statins; The two sides of the dispute; Press reports that have led to fears of a consumer backlash against the drugs.

  • The limited precision of phase I trials. Christian, Michaele C.; Korn, Edward L. // JNCI: Journal of the National Cancer Institute;11/16/94, Vol. 86 Issue 22, p1662 

    Editorial. Criticizes conventional phase I trial designs' tendency to give inappropriate dose recommendations. National Cancer Institute (NCI) Cancer Therapy Evaluation Program's commitment to exploring alternative phase I trial designs; Strategies for improving precision of estimating the...

  • Toxicity tests minus animals? Gillis, Anna Maria // BioScience;Mar1993, Vol. 43 Issue 3, p137 

    Reports that cellular and tissue techniques are in, but as long as public safety is at stake, animals will continue to be used in testing. The work of toxicology; In vitro models; Human skin modeling; What tests can determine; Characteristics of a proper model; Validation.

  • Precocious puberty.  // Discover;Jul92, Vol. 13 Issue 7, p13 

    Studies the medical condition known as precocious puberty. Symptoms; New drug, called histrelin acetate, that shows promise in treating precocious puberty, particularly in girls; High cost of the drug; Future prospects.

  • The European Medicines Evaluation Agency. Herxheimer, Andrew // BMJ: British Medical Journal (International Edition);2/17/96, Vol. 312 Issue 7028, p394 

    Focuses on the efforts of the European Medicines Evaluation Agency (EMEA) to implement a European drug registration system. Facilitation of the free movement of drugs within the European Union; Provision of rigorous scientific evaluation of new products; Efforts to give patients quick access to...

  • Clot-busters war: Science by press release. Levin, Arthur A. // HealthFacts;Jun93, Vol. 18 Issue 169, p2 

    Reports on the contradictory results of published studies regarding the efficacy and safety of the clot-dissolving drug t-PA over its cheaper rival streptokinase. Public relations hype versus objective science; Genentech's claim on t-PA's efficacy; British epidemiologist Richard Peto's analysis...

  • Kids get new upset-stomach remedy.  // Drug Store News;12/10/2007, Vol. 29 Issue 15, p37 

    The article evaluates the Tums Kids' stomach relief product from the GlaxoSmithKline company.

  • Trials to assess equivalence: The importance of rigorous methods. Jones, B.; Jarvis, P. // BMJ: British Medical Journal (International Edition);07/16/96, Vol. 313 Issue 7048, p36 

    Describes the methodological issues that surround equivalence trials in drug efficacy tests. Implications of these methodological issues; Factors behind the need for equivalence tests to be larger than their placebo controlled counterparts. INSETS: Example of sample size calculation.;Example:...

  • Assessment of new drugs: a clinical pharmacologist's view. Breckenridge, A.M. // British Medical Journal;5/31/1980, Vol. 280 Issue 6227, p1303 

    Focuses on the role of clinical pharmacologist in the assessment of new drugs in Great Britain. Phases in assessing chemical entities in man; Clinical testing of new chemical entities; Problems encountered by the pharmaceuticals industry in drug assessment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics